Osteoprotegerin levels in patients with severe mental disorders

Journal of Psychiatry and Neuroscience

Volumn 35, Issue 5, 2010, Pages 304-310

  Hope, Sigrun ^a,b   Melle, Ingrid ^b   Aukrust, Pål ^c   Agartz, Ingrid ^d   Lorentzen, Steinar ^b   Steen, Nils Eiel ^e   Djurovic, Srdjan ^f   Ueland, Thor ^d   Andreassen, Ole A ^g  

^a Oslash stfold Hospital   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e DIAKONHJEMMET HOSPITAL   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; OSTEOPROTEGERIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; AUTOIMMUNE DISEASE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BRAIN CALCIFICATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENCEPHALITIS; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SEX DIFFERENCE; SMOKING; SUBSTANCE ABUSE;

EID: 77956527531     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: 10.1503/jpn.090088     Document Type: Article

References (54)

1. Burmeister M, McInnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet 2008;9:527-40.
2. Lichtenstein P, Yip B, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009;373:234-9.
3. Brown AS. The risk for schizophrenia from childhood and adult infections. Am J Psychiatry 2008;165:7-10.
4. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-8.
5. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1355-61.
6. Kim YK, Jung HG, Myint AM, et al. Imbalance between proinflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-5.
7. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008;65:395-407.
8. Webster Marketon JI, Glaser R. Stress hormones and immune function. Cell Immunol 2008;252:16-26.
9. Brydon L, Walker C, Wawrzyniak A, et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2009;23:217-24.
10. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13:501-10.
11. McAfoose J. Evidence of a cytokine model for cognitive function. Neurosci Biobehav Rev 2009;33:355-66.
12. Viviani B, Bartesaghi S, Corsini E, et al. Cytokines role in neurodegenerative events. Toxicol Lett 2004;149:85-9.
13. Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: A role in endothelial physiopathology? Front Biosci 2008;13:135-47.
14. Jorsal A, Tarnow L, Flyvbjerg A, et al. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008;51:2100-7.
15. Frost ML, Grella R, Millasseau SC, et al. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int 2008;83:112-20.
16. Baud'huin M, Lamoureux F, Duplomb L, et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007;64:2334-50.
17. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33.
18. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86: 631-7.
19. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007;50:2218-25.
20. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008;159:603-8.
21. Semb A, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009;29:975-80.
22. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007;68:917-23.
23. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007;24:481-5.
24. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-50.
25. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
26. Hanson DR, Gottesman II. Theories of schizophrenia: a geneticinflammatory- vascular synthesis. BMC Med Genet 2005;6:7.
27. First MB, Spitzer RL, Miriam G, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
28. Pedersen G, Hagtvet KA, Karterud S. Generalizability studies of the Global Assessment of Functioning-Split version. Compr Psychiatry 2007;48:88-94.
29. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIMEMD 1000 study. JAMA 1994;272:1749-56.
30. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 2001;145:685-90.
31. Wu TL, Tsao KC, Chang CP, et al. Development of ELISA on mi croplate for serum C-reactive protein and establishment of agedependent normal reference range. Clin Chim Acta 2002;322:163-8.
32. Sugino H, Futamura T, Mitsumoto Y, et al. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:303-7.
33. Drexhage R, Knijff E, Padmos R, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010;10:59-76
34. Kahl KG, Greggersen W, Rudolf S, et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 2006; 68: 669-74.
35. Kahl KG, Rudolf S, Dibbelt L, et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporos Int 2005;16:424-9.
36. Guldiken B, Guldiken S, Turgut B, et al. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007;120:511-6.
37. Strand M, Soderstrom I, Wiklund PG, et al. Polymorphisms at the osteoprotegerin and interleukin-6 genes in relation to first-ever stroke. Cerebrovasc Dis 2007;24:418-25.
38. Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007;68:1032-8.
39. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008;34:354-66.
40. Moorhead TW, McKirdy J, Sussmann JE, et al. Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry 2007; 62: 894-900.
41. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42.
42. Jensen JK, Ueland T, Atar D, et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2009;267:410-7.
43. Hofsø D, Ueland T, Hager H, et al. Inflammatory mediators in and changes after oral glucose. Eur J Endocrinol 2009;161:451-8.
44. Gannagé-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to bydy weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008;158:353-9.
45. Rybakowski J, Skibinska M, Kapelski P, et al. Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophr Res 2009;109:90-3.
46. Rybakowski J, Skibinska M, Leszczynska-Rodziewicz A, et al. Matrix metalloproteinase gene and bipolar mood disorder. Neuromolecular Med 2009;11:128-32.
47. Theoleyre S, Wittrant Y, Couillaud S, et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim Biophys Acta 2004;1644:1-7.
48. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/ RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8.
49. Takami M, Takahashi N, Udagawa N, et al. Intracellular calcium and protein kinase C mediate expression of receptor activator ofnuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000;141:4711-9.
50. Bergh JJ, Xu Y, Farach-Carson MC. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. Endocrinology 2004;145:426-36.
51. Li Y, Hu X, Liu Y, et al. Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacology 2009;56:580-9.
52. Coon D, Gulati A, Cowan C, et al. The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J Endod 2007;33:432-6.
53. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90:179-85.
54. Drzyzga L, Obuchowicz E, Marcinowska A, et al. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006;20:532-45